Perflenapent

Summary

Perflenapent (CHEMBL1899801) is an approved small-molecule radioopaque medium (ATC V08DA03); indicated across 3 conditions including glioblastoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V08DA03
• Indications: 3 conditions
• Clinical trials: 2
• Chemistry: 288.03 Da · C5F12

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1899801
Name	Perflenapent
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	12675
ChEBI	CHEBI:39428
ATC	V08DA03
Molecular formula	C5F12
Molecular weight	288.03
InChIKey	NJCBUSHGCBERSK-UHFFFAOYSA-N

SMILES: C(C(C(F)(F)F)(F)F)(C(C(F)(F)F)(F)F)(F)F

IUPAC name: 1,1,1,2,2,3,3,4,4,5,5,5-dodecafluoropentane

ChEBI definition: A fluorocarbon that is pentane in which all of the hydrogens have been replaced by fluorines.

Pharmacological roles (ChEBI): radioopaque medium.

Also known as: Dodecafluoropentane, Echogen, Nvx-108, NVX-108, Perflenapent, SID50112673, PERFLENAPENT, SID144205977

Patent coverage: 3,348 distinct patent families (9,794 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
glioblastoma	1	MONDO:0018177	EFO:0000519

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06658535	PHASE1	RECRUITING	A Dose Escalation Study of NanO2 in Patients With Mild Respiratory Distress
NCT02189109	PHASE1	COMPLETED	The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).